Aerocrine enters distribution agreement with Phadia in France

SOLNA – 20 December, 2007 – Aerocrine AB (OMX Nordic Exchange: AERO) announces that the company has entered into a distribution agreement with Phadia France.

As of 1 January 2008, Aerocrine has granted Phadia the right to market and sell NIOX MINO® on the French market. Phadia, a world-leader within allergy diagnostics, already sells Aerocrine products
in Spain.

In France about 4 million people have diagnosed asthma and the prevalence of asthma like symptoms is even higher, about 15%.

“Phadia has an established market position in France in addition to good knowledge of our products. We look forward to working together with Phadia to launch Aerocrine’s products in France,” says Paul de Potocki, CEO of Aerocrine.

“Through Phadia’s distribution of NIOX MINO in Spain, we have established a strong relationship with Aerocrine and have developed a good understanding of patient benefits from the company’s products. We are pleased to be entrusted with selling Aerocrine’s products in France as well,” says Magnus Lundberg, CEO of Phadia.

For more information, contact

Paul de Potocki, CEO Aerocrine, telephone: +46 8 629 07 82

Santiago Pulido, Senior Vice President Phadia, telephone: +34 639 82 01 26